Pant Shubham, Shapiro Charles L
The Comprehensive Breast Health Services, Arthur G. James Cancer Hospital and Richard J. Solve Research Institute, The Ohio State University Medical Center, Columbus, Ohio 43210, USA.
Drugs. 2008;68(18):2591-600. doi: 10.2165/0003495-200868180-00005.
Aromatase inhibitors (AIs) are standard treatments for postmenopausal women with estrogen responsive breast cancers. The mechanism of AIs, inhibition of the aromatase enzyme that causes decreases in endogenous estrogens, is responsible for bone loss and increased fractures. Screening and prevention of AI-induced bone loss closely follows the standard recommendations for postmenopausal osteoporosis. Lifestyle changes such as increasing physical activity and weight-bearing exercise, stopping smoking, and taking adequate amounts of daily calcium and vitamin D promote bone and overall health. Bisphosphonates are specific inhibitors of osteoclasts and reduce bone loss in women treated with AIs. The optimal dose administration schedule and duration of bisphosphonate treatment for AI-induced bone loss remains undefined.
芳香化酶抑制剂（AIs）是雌激素反应性乳腺癌绝经后女性的标准治疗药物。AIs的作用机制是抑制芳香化酶，导致内源性雌激素减少，这是导致骨质流失和骨折增加的原因。AI引起的骨质流失的筛查和预防严格遵循绝经后骨质疏松症的标准建议。生活方式的改变，如增加体育活动和负重锻炼、戒烟以及每日摄入足够的钙和维生素D，可促进骨骼健康和整体健康。双膦酸盐是破骨细胞的特异性抑制剂，可减少接受AIs治疗的女性的骨质流失。双膦酸盐治疗AI引起的骨质流失的最佳剂量给药方案和持续时间仍不明确。
